<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugSwotsOutput xmlns:ns2="local"><SWOTs><SWOT><Class>COX-2 inhibitors</Class><Strengths><Strength name="Strength" sortOrder="1">&lt;para&gt;Market-leading COX-2 inhibitor [Cortellis]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="2">&lt;para&gt;Broad label, covering adult and juvenile rheumatoid arthritis (JRA), osteoarthritis (OA) and ankylosing spondylitis (AS), acute pain and primary dysmenorrhea [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="3">&lt;para&gt;Improved the WOMAC index, a composite of pain, stiffness and functional measures, across the pivotal trial program in OA, and significantly reduced pain during OA flare within 24 to 48 h [&lt;ulink linkType="Reference" linkID="404726"&gt;404726&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="4">&lt;para&gt;Significantly reduced joint tenderness, pain and swelling in patients with RA, with comparable efficacy to naproxen [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="5">&lt;para&gt;Response rate was 80% in patients with polyarticular JRA or systemic onset JRA, compared to 67% for naproxen [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="6">&lt;para&gt;Improved measures of global pain intensity, global disease activity and functional impairment in patients with AS [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="7">&lt;para&gt;Associated with significantly fewer upper GI ulcers than both naproxen and ibuprofen [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Strength></Strengths><Weaknesses><Weakness name="Weakness" sortOrder="1">&lt;para&gt;Twice-daily dosing [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="10">&lt;para&gt;US patent protection expired in December 2014, and generics entered immediately [&lt;ulink linkType="Reference" linkID="1085323"&gt;1085323&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="2">&lt;para&gt;Label carries a boxed warning highlighting the risk of cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, and serious gastrointestinal adverse events including bleeding, ulceration and perforation [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="3">&lt;para&gt;The most common adverse events observed in clinical trials were abdominal pain, diarrhea and dyspepsia [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="4">&lt;para&gt;The label recommends the lowest effective dose for the shortest duration consistent with treatment goals [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="5">&lt;para&gt;Significant drug interactions, including warfarin, lithium, ACE inhibitors and aspirin [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="6">&lt;para&gt;Contraindicated in pregnant women from 30 weeks gestation due to the risk of premature closure of the ductus arteriosus in the fetus [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="7">&lt;para&gt;Also contraindicated for use in peri-operative pain in coronary artery bypass (CABG) due to an increased incidence of MI and stroke [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="8">&lt;para&gt;Development for chronic pain was discontinued following an FDA complete response letter in 2010 [&lt;ulink linkType="Reference" linkID="1706880"&gt;1706880&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1172256"&gt;1172256&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="9">&lt;para&gt;Withdrawn for familial adenomatous polyposis (FAP) in the US and EU, as the company was unable to provide long-term data to demonstrate efficacy in reducing the number of colorectal polyps in FAP [&lt;ulink linkType="Reference" linkID="479958"&gt;479958&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182110"&gt;1182110&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1355696"&gt;1355696&lt;/ulink&gt;]&lt;/para&gt;</Weakness></Weaknesses><Opportunities><Opportunity name="Opportunity" sortOrder="1">&lt;para&gt;OA is one of the most common forms of degenerative joint disease, which can occur in any joint, and treatment is aggressively pursued as reduction in symptoms can help patients to stay active and possibly slow the progression of the disease; incidence is also increasing due to rapidly aging populations and increasing obesity [&lt;ulink linkType="Reference" linkID="1312816"&gt;1312816&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="2">&lt;para&gt;The lack of effective pharmacotherapy capable of restoring the original structure and function of damaged cartilage and synovial tissue in patients with OA; the industry has tried and failed to provide effective disease-modifying osteoarthritic drugs [&lt;ulink linkType="Reference" linkID="1728286"&gt;1728286&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="3">&lt;para&gt;Approximately 50% of OA patients do not respond to first-line acetaminophen [&lt;ulink linkType="Reference" linkID="1323020"&gt;1323020&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="4">&lt;para&gt;Patients with rheumatic disorders often require long-term therapy [&lt;ulink linkType="Reference" linkID="1312338"&gt;1312338&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="5">&lt;para&gt;Development delays for &lt;ulink linkType="Drug" linkID="11703"&gt;naproxcinod&lt;/ulink&gt;, the most advanced in a new class of anti-inflammatories (cyclooxygenase-inhibiting nitric oxide donators) â€“ following an approvable letter in mid-2010, new developer &lt;ulink linkType="Company" linkID="1048705"&gt;Fera&lt;/ulink&gt; is liaising with the FDA on further clinical trials required. It had been hoped the class would combine the efficacy of COX inhibitors with improved gastrointestinal safety [&lt;ulink linkType="Reference" linkID="1711770"&gt;1711770&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1117806"&gt;1117806&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="6">&lt;para&gt;Low back pain is a major health concern, affecting most adults at some point in their life [&lt;ulink linkType="Reference" linkID="1204544"&gt;1204544&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1312472"&gt;1312472&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="7">&lt;para&gt;Primary dysmenorrhea is extremely common, with prevalence rates of up to 90% [&lt;ulink linkType="Reference" linkID="1355961"&gt;1355961&lt;/ulink&gt;]&lt;/para&gt;</Opportunity></Opportunities><Threats><Threat name="Threat" sortOrder="1">&lt;para&gt;Generic losses following generic entry in December 2014 [&lt;ulink linkType="Reference" linkID="1620470"&gt;1620470&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1619733"&gt;1619733&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1619805"&gt;1619805&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1621240"&gt;1621240&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="2">&lt;para&gt;Acetaminophen is widely regarded as the first-line drug treatment of choice for mild-to-moderate OA pain [&lt;ulink linkType="Reference" linkID="1311808"&gt;1311808&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="3">&lt;para&gt;Non-pharmacologic interventions such as rest, weight loss, physical therapy and orthoses (devices which help to keep joints aligned and functioning correctly) are non-pharmacologic strategies which can substantially improve OA symptoms, and these are usually the first treatments recommended [&lt;ulink linkType="Reference" linkID="1313377"&gt;1313377&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="4">&lt;para&gt;NSAIDs usually become ineffective for severe OA, and most patients turn to steroid joint injections, arthroscopy and joint irrigation, cartilage grafting or joint replacement [&lt;ulink linkType="Reference" linkID="1728392"&gt;1728392&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="5">&lt;para&gt;Declining use for RA, due to increasing use of aggressive early therapy with disease-modifying anti-rheumatic drugs, particularly biologics [&lt;ulink linkType="Reference" linkID="1312391"&gt;1312391&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="6">&lt;para&gt;Decline in COX-2 inhibitor prescriptions due to concerns over the class&amp;apos;s cardiovascular safety following the withdrawal of &lt;ulink linkType="Drug" linkID="15472"&gt;Vioxx&lt;/ulink&gt; in 2004 and &lt;ulink linkType="Drug" linkID="17856"&gt;Bextra&lt;/ulink&gt; in 2005 [&lt;ulink linkType="Reference" linkID="561739"&gt;561739&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="594102"&gt;594102&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1313759"&gt;1313759&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="7">&lt;para&gt;Use of non-specific NSAIDs such as diclofenac, ibuprofen and naproxen; these products are extremely familiar to prescribers and patients, and the market is highly generic [&lt;ulink linkType="Reference" linkID="1312338"&gt;1312338&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="8">&lt;para&gt;&lt;b&gt;Last updated on February 1, 2016&lt;/b&gt;&lt;/para&gt;</Threat></Threats></SWOT></SWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugSwotsOutput>